Healthcare -
Medical - Distribution - NASDAQ - US
$ 2.49
3.32 %
$ 75.3 M
Market Cap
-10.38
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart ZYXI
FINANCIALS
Balance Sheet
Zynex, Inc.
| Current Assets | 75.2 M |
| Cash & Short-Term Investments | 39.6 M |
| Receivables | 18 M |
| Other Current Assets | 17.5 M |
| Non-Current Assets | 46.9 M |
| Long-Term Investments | 0 |
| PP&E | 12.9 M |
| Other Non-Current Assets | 34 M |
| Current Liabilities | 16.9 M |
| Accounts Payable | 7.09 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 9.77 M |
| Non-Current Liabilities | 69.5 M |
| Long-Term Debt | 58.6 M |
| Other Non-Current Liabilities | 10.9 M |
EFFICIENCY
Earnings Waterfall
Zynex, Inc.
| Revenue | 192 M |
| Cost Of Revenue | 39.4 M |
| Gross Profit | 153 M |
| Operating Expenses | 147 M |
| Operating Income | 5.99 M |
| Other Expenses | 3 M |
| Net Income | 2.99 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Zynex, Inc.
| Net Income | 2.99 M |
| Depreciation & Amortization | 4.78 M |
| Capital Expenditures | -578 K |
| Stock-Based Compensation | 2.99 M |
| Change in Working Capital | 0 |
| Others | 2.89 M |
| Free Cash Flow | 12.1 M |
Wall Street Analysts Price Targets
Zynex, Inc.
Wall Street analysts predict an average 1-year price target for ZYXI of $13.2 , with forecasts ranging from
a
low of
$11 to a high of $16 .
ZYXI Lowest Price Target
Wall Street Target
11 USD
341.77%
ZYXI Average Price Target
Wall Street Target
13.2 USD
428.78%
ZYXI Highest Price Target
Wall Street Target
16 USD
542.57%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.0909 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Zynex, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
227 K USD 1
6-9 MONTHS
376 K USD 2
9-12 MONTHS
323 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
58.2 K USD 1
9-12 MONTHS
7. News
Lost Money on Zynex, Inc. (ZYXI)? Contact Levi & Korsinsky Before May 19, 2025 to Join Class Action
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Zynex, Inc. (NASDAQ:ZYXI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-form?prid=149275&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 1 month ago
Zynex, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; May 19, 2025 Deadline to file Lead Plaintiff Motion
Investors can contact the law firm at no cost to learn more about recovering their losses
globenewswire.com
- 1 month ago
ZYXI Deadline: ZYXI Investors with Losses in Excess of $100K Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit
NEW YORK , May 19, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the "Class Period"), of the important May 19, 2025 lead plaintiff deadline. So What: If you purchased Zynex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
prnewswire.com
- 1 month ago
ZYXI LAWSUIT ALERT: Levi & Korsinsky Notifies Zynex, Inc. Investors - Lead Plaintiff Deadline May 19, 2025
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Zynex, Inc. (NASDAQ:ZYXI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-form?prid=149257&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 1 month ago
ZYXI Investors Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--ZYXI Investors Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
businesswire.com
- 1 month ago
ZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zynex, Inc. (“Zynex” or “the Company”) (NASDAQ: ZYXI) and certain of its officers.
globenewswire.com
- 1 month ago
ZYXI DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Zynex, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 19 Deadline in Securities Class Action – ZYXI
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the “Class Period”), of the important May 19, 2025 lead plaintiff deadline.
globenewswire.com
- 1 month ago
May 19, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ZYXI
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (NASDAQ: ZYXI) of a class action securities lawsuit.
globenewswire.com
- 1 month ago
Investors who lost money on Zynex, Inc.(ZYXI) should contact The Gross Law Firm about pending Class Action - ZYXI
NEW YORK , May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (NASDAQ: ZYXI). Shareholders who purchased shares of ZYXI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
prnewswire.com
- 1 month ago
Securities Lawsuit Alert: Zynex, Inc. (ZYXI) - Contact Levi & Korsinsky Before May 19, 2025
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Zynex, Inc. (NASDAQ:ZYXI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-form?prid=149234&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 1 month ago
May 19, 2025 Deadline: Join Class Action Lawsuit Against Zynex, Inc. (ZYXI) - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Zynex, Inc. (NASDAQ:ZYXI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-form?prid=149215&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zynex, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZYXI
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Zynex, Inc. ("Zynex" or the "Company") (NASDAQ:ZYXI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
accessnewswire.com
- 1 month ago
8. Profile
Summary
Zynex, Inc. ZYXI
COUNTRY
US
INDUSTRY
Medical - Distribution
MARKET CAP
$ 75.3 M
Dividend Yield
0.00%
Description
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Contact
9655 Maroon Circle, Englewood, CO, 80112
https://www.zynex.com
IPO
Date
Feb. 25, 2004
Employees
1000
Officers
Mr. Neil Friery
Chief Operating Officer of Zynex Monitoring Solutions, Inc.
Mr. Steve Fox
Executive Vice President of Sales
Mr. Thomas Sandgaard
Founder, President, Chief Executive Officer & Chairman
Mr. Daniel J. Moorhead CPA
Chief Financial Officer
Ms. Anna Lucsok
Chief Operating Officer
Mr. Donald Gregg
President of Zynex Monitoring Solutions